A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study.

Discov Oncol · 2025 · PMC12106252 · PMID 40418300

Europe PMC DOI

hedged sentence

0.1140

closest p · 2.3× alpha

0.1140

boldest claim

The sentences

showed a trendP = 0.114not close (p > 0.1)

In the population aged < 65 years, patients in the E + dCRT group also showed a trend of better 3-year PFS rate (54.29% [95% CI 36.61–68.98] vs. 33.33% [95% CI 13.65–54.54]; HR for disease progression, 0.58; 95% CI 0.27–1.22; P = 0.114) and 3-year OS rate (80.00% [95% CI 62.58–89.92] vs. 55.56% [95% CI 30.51–74.75]; HR for death, 0.54; 95% CI 0.23–1.23; P = 0.102) compared to those in the dCRT group (Fig. 3 E and F).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.